Is Palantir Stock Overvalued?
By every traditional yardstick, including a price‑to‑sales well above 100,…
Sell
42
ANIP Quote, Financials, Valuation and Earnings
Last price:
$62.52
Seasonality move
:
-4.71%
Day range:
$61.18 - $62.58
52-week range:
$52.50 - $77.00
Dividend yield:
0%
P/E ratio:
55.43x
P/S ratio:
1.81x
P/B ratio:
3.24x
Volume:
150.7K
Avg. volume:
392.5K
1-year change:
-1.08%
Market cap:
$1.4B
Revenue:
$614.4M
EPS (TTM):
-$1.27
Analysts' Opinion
-
Consensus RatingANI Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $81.17, ANI Pharmaceuticals has an estimated upside of 29.74% from its current price of $62.56.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $65.00 representing 100% downside risk from its current price of $62.56.
Fair Value
-
According to the consensus of 4 analysts, ANI Pharmaceuticals has 29.74% upside to fair value with a price target of $81.17 per share.
ANIP vs. S&P 500
-
Over the past 5 trading days, ANI Pharmaceuticals has overperformed the S&P 500 by 1.36% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
ANI Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ANI Pharmaceuticals has grown year-over-year revenues for 14 quarters straight. In the most recent quarter ANI Pharmaceuticals reported revenues of $197.1M.
Earnings Growth
-
ANI Pharmaceuticals earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter ANI Pharmaceuticals reported earnings per share of $0.69.
Enterprise value:
1.8B
EV / Invested capital:
--
Price / LTM sales:
1.81x
EV / EBIT:
182.88x
EV / Revenue:
2.74x
PEG ratio (5yr expected):
--
EV / Free cash flow:
38.07x
Price / Operating cash flow:
25.21x
Enterprise value / EBITDA:
27.62x
Gross Profit (TTM):
$400M
Return On Assets:
-1.85%
Net Income Margin (TTM):
-3.12%
Return On Equity:
-4.66%
Return On Invested Capital:
-2.24%
Operating Margin:
7.15%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $358.7M | $517.5M | $674.1M | $137.4M | $197.1M | |
| Gross Profit | $216.5M | $324.5M | $400M | $88.3M | $124.1M | |
| Operating Income | $4.7M | $52.6M | $1.3M | $15.1M | $14.1M | |
| EBITDA | $54.3M | $126.7M | $66.9M | $44.6M | $48.4M | |
| Diluted EPS | -$1.71 | $1.58 | -$1.27 | $0.82 | $0.69 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $182.8M | $301.4M | $364.8M | $540.6M | $536.3M | |
| Total Assets | $463.8M | $744.8M | $765.2M | $914.5M | $1.3B | |
| Current Liabilities | $82.8M | $79.5M | $125.8M | $136.9M | $201.8M | |
| Total Liabilities | $260.1M | $398.8M | $425.7M | $437.7M | $849M | |
| Total Equity | $203.7M | $346.1M | $339.5M | $476.8M | $443.5M | |
| Total Debt | $183.4M | $287.2M | $286.3M | $285.5M | $622.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $9.2M | $115.8M | $80.7M | $18.3M | $35M | |
| Cash From Investing | -$15.9M | -$7.2M | -$433.5M | $8.9M | -$19.8M | |
| Cash From Financing | -$7.4M | $52.3M | $274.8M | -$19.7M | -$9.9M | |
| Free Cash Flow | -$7.5M | $95.1M | $48.5M | $13.7M | $15.1M | |
ANIP
Sector
Market Cap
$1.4B
$33.4M
Price % of 52-Week High
81.25%
46.84%
Dividend Yield
0%
0%
Shareholder Yield
-3.8%
-0.6%
1-Year Price Total Return
-1.08%
-37.4%
Beta (5-Year)
0.548
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
-7.72%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$62.02
200-day SMA
Buy
Level
$60.43
Bollinger Bands (100)
Sell
Level
58.43 - 67.59
Chaikin Money Flow
Sell
Level
-224.6M
20-day SMA
Buy
Level
$60.39
Relative Strength Index (RSI14)
Buy
Level
51.01
ADX Line
Buy
Level
13.63
Williams %R
Neutral
Level
-26.5449
50-day SMA
Sell
Level
$64.91
MACD (12, 26)
Sell
Level
-0.49
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Neutral
Level
56.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.5057)
Sell
CA Score
(Annual)
Level (-0.7002)
Buy
Beneish M-Score
(Annual)
Level (-2.3961)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (0.1128)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Stock Forecast FAQ
In the current month, ANIP has received 3 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ANIP average analyst price target in the past 3 months is $81.17.
-
Where Will ANI Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that ANI Pharmaceuticals share price will rise to $81.17 per share over the next 12 months.
-
What Do Analysts Say About ANI Pharmaceuticals?
Analysts are divided on their view about ANI Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ANI Pharmaceuticals is a Sell and believe this share price will drop from its current level to $65.00.
-
What Is ANI Pharmaceuticals's Price Target?
The price target for ANI Pharmaceuticals over the next 1-year time period is forecast to be $81.17 according to 4 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ANIP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ANI Pharmaceuticals is a Buy. 3 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ANIP?
You can purchase shares of ANI Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ANI Pharmaceuticals shares.
-
What Is The ANI Pharmaceuticals Share Price Today?
ANI Pharmaceuticals was last trading at $62.52 per share. This represents the most recent stock quote for ANI Pharmaceuticals. Yesterday, ANI Pharmaceuticals closed at $62.56 per share.
-
How To Buy ANI Pharmaceuticals Stock Online?
In order to purchase ANI Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Gamestop’s Bitcoin Strategy Going To Succeed?
When GameStop (NYSE: GME) announced in Q1 that its board had…
How High Will Roku Stock Go?
Streaming software and hardware maker Roku (NASDAQ:ROKU) has seen its…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Sell
11
VEON alert for Jun 14
VEON [VEON] is down 18.57% over the past day.
Buy
74
DAVE alert for Jun 14
Dave [DAVE] is down 12.68% over the past day.
Buy
54
DAR alert for Jun 14
Darling Ingredients [DAR] is up 9.12% over the past day.
